| Literature DB >> 34070614 |
Anallely López-Yerena1, Inés Domínguez-López1, Anna Vallverdú-Queralt1,2, Maria Pérez1,3, Olga Jáuregui4,5, Elvira Escribano-Ferrer2,6,7, Rosa M Lamuela-Raventós1,2.
Abstract
In the search for natural products with properties that may protect against or slow down chronic and degenerative diseases (e.g., cancer, and cardiovascular and neurodegenerative conditions), phenolic compounds (PC) with benefits for human health have been identified. The biological effects of PC in vivo depend on their bioavailability, intestinal absorption, metabolism, and interaction with target tissues. The identification of phenolic compounds metabolites (PCM), in biological samples, after food ingestion rich in PC is a first step to understand the overall effect on human health. However, their wide range of physicochemical properties, levels of abundance, and lack of reference standards, renders its identification and quantification a challenging task for existing analytical platforms. The most frequent approaches to metabolomics analysis combine mass spectrometry and NMR, parallel technologies that provide an overview of the metabolome and high-power compound elucidation. In this scenario, the aim of this review is to summarize the pre-analytical separation processes for plasma and urine samples and the technologies applied in quantitative and qualitative analysis of PCM. Additionally, a comparison of targeted and non-targeted approaches is presented, not available in previous reviews, which may be useful for future metabolomics studies of PCM.Entities:
Keywords: LC/MS; NMR; metabolites; phenolic compounds; plasma; sample treatment; urine
Year: 2021 PMID: 34070614 PMCID: PMC8229076 DOI: 10.3390/antiox10060846
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Food source of phenolic compounds and the predominant phenolic compound metabolites identified in plasma and urine samples.
| Food or Supplement | Compounds | Metabolites | Sample | Ref |
|---|---|---|---|---|
| VOO/EVOO | Phenolic acids and tyrosols | PI | Plasma | [ |
| Oleuropein | Urine | [ | ||
| Hydroxytyrosol | PII | [ | ||
| Tyrosols | [ | |||
| Phenolic acids and tyrosols | Plasma | [ | ||
| Hydroxytyrosol | [ | |||
| Flavones, lignans, and tyrosols | PI/PII | Urine | [ | |
| Tyrosols | [ | |||
| Secoiridoids | Plasma/urine | [ | ||
| Hydroxytyrosol and derivatives | PII/MM | [ | ||
| Coffee | Chlorogenic acids | PII/MM | Plasma/urine | [ |
| Phenolic acids | [ | |||
| PI | [ | |||
| PII | Plasma | [ | ||
| MM | [ | |||
| Green tea | Flavan-3-ols | PII | Urine | [ |
| PII/MM | [ | |||
| Black tea | Hydroxybenzoic acids | [ | ||
| Flavonoids and phenolic acids | Plasma/urine | [ | ||
| Yerba mate | Flavonols and phenolic acids | [ | ||
| Orange juice | Flavonoids and phenolic acids | PII | Plasma/urine | [ |
| Flavanones and flavonols | Urine | [ | ||
| Flavanoids | PII/MM | [ | ||
| Flavanones | [ | |||
| Plasma/urine | [ | |||
| Red wine | Flavonoids, phenolic acids, lignans, stilbenes | PII/MM | Urine | [ |
| Stilbenes | [ | |||
| Proanthocyanidin | Plasma/urine | [ | ||
| Bilberry | Anthocyanins | PII | Plasma/urine | [ |
| Black raspberry | Anthocyanins | PII | Urine | [ |
| Red raspberry | Flavan-3-ols and phenolic acids | PII/MM | Plasma/urine | [ |
| Chokeberry extract | Anthocyanins | PI/PII | Urine | [ |
| Strawberry drink | Anthocyanins | PII | Plasma | [ |
| Anthocyanins and phenolic acids | PII/MM | [ | ||
| Cranberry juice | Flavonols, flavan-3-ols, and phenolic acids | PII/MM | Plasma/urine | [ |
| Flavan-3-ols | [ | |||
| Cranberry extract | Procyanidins | PII/MM | Plasma | [ |
| Cranberry-syrup | Flavonoids and phenolic acids | PI/PII | Urine | [ |
| Grape pomace drink | Flavan-3-ols and phenolic acids | PII/MM | Plasma/urine | [ |
| Concord grape juice | Flavonoids and hydroxycinnamic acids | PII | Plasma/urine | [ |
| Phenolic acids | MM | Urine | [ | |
| Grape extract | Flavonoids, phenolic acids, and stilbenes | PII/MM | Urine | [ |
| PRJD | Flavonoids and phenolic acids | PII/MM | Plasma/urine | [ |
| PRBF | Flavonoids and phenolic acids | PII | Urine | [ |
| Apple | Flavonoids and phenolic acids | PII/MM | Plasma | [ |
| Flavan-3-ol | Urine | [ | ||
| AAPO | Quercetin | PII | Plasma | [ |
| Cocoa | Flavan-3-ols and phenolic acids | MM | Urine | [ |
| Flavonoids and procyanidin | PII/MM | Plasma/urine | [ | |
| Flavan-3-ols | [ | |||
| Cocoa cream | Flavan-3-ols | PII | Plasma | [ |
| Cocoa drink | [ | |||
| Plasma/urine | [ | |||
| (-)-Epicatechin | Urine | [ | ||
| Dark chocolate/ | Flavan-3-ols | PII | Plasma/urine | [ |
| Isoflavones | Urine | [ | ||
| Flavan-3-ols | PII/MM | [ | ||
| Tomato sauce | Flavonoids and phenolic acids | PII | Plasma/urine | [ |
| Tomato sauce with oil | Flavanones and hydroxycinnamic acids | [ | ||
| Tomato/tomato sauce | Flavonoids and phenolic acids | PII/MM | [ | |
| Almonds | Flavonoids | PII/MM | Plasma/urine | [ |
| Beans | Flavonoids and phenolic acids | PII/MM | Plasma/urine | [ |
| Black soybean extract | Isoflavones | PII | Plasma/urine | [ |
| Standard solutions | Catechin | PII/MM | Urine | [ |
| Quercetin | Plasma/urine | [ | ||
| (-)-Epicatechin | PI/PII/MM | [ | ||
| Daidzein | [ | |||
| Gallic acid | PII | [ | ||
| Trans-resveratrol | Urine | [ | ||
| Caffeic, ferulic, and isoferulic acid | PI/PII | Plasma/urine | [ | |
| Hesperetin and hesperidin | [ | |||
| Oleocanthal | Plasma | [ | ||
| Oleacein | [ | |||
| Capsule | (-)-Epicatechin and procyanidins | PII/MM | Plasma/urine | [ |
| Luteolin | PII | Plasma | [ | |
| Pill | Trans-resveratrol | PII/MM | Plasma | [ |
PI: Phase I metabolites; PII: Phase II metabolites; MM: microbial metabolites; VOO: Virgin olive oil; EVOO: Extra virgin olive oil. PRJD: Polyphenol-rich juice drink, PRBF: Puree of (poly)phenol-rich berry fruits; AAPO: Applesauce with apple peel and onion.
Figure 1Graphical representation of plasma and urine clean-up and the bioanalysis for the identification and quantification of phenolic metabolites.
Methods for untargeted analysis of PCM in urine and plasma samples.
| Phenolic Compounds | Sample; Sample Clean-Up; Internal Standard | Chromatographic Conditions | MS Conditions |
|---|---|---|---|
|
| |||
| Quercetin [ | Urine and plasma; PP | Acquity BEH C18 (2.1 × 50 mm, 1.7 μm); A: Water (0.1% FA). B: ACN. | QTOF; ESI-[M−H]− |
| Secoiridoids [ | Urine and plasma; UU and PP | Hypersil gold C18 (2.1 × 100 mm, 1.9 μm); A: Water (0.01% AA), B: ACN. | Q-Exactive; ESI-[M−H]− |
| Epicatechin [ | Urine and plasma; SPE | Acquity BEH C18 (2.1 × 100 mm, 1.7 μm); A: Water (0.1% FA), A: ACN:MeOH (3:1 | LTQ-Orbitrap; ESI-[M−H]− |
| Daidzein [ | Acquity BEH C18 (2.1 × 100 mm, 1.7 μm); A: Water (0.1% FA). B: ACN. | LTQ-Orbitrap; ESI-[M−H]−/[M+H]+ | |
| Oleocanthal [ | Plasma; SPE | Acquity BEH C18 (2.1 × 50 mm, 1.7 μm); A: Water, B: MeOH, both with 0.1% FA. | LTQ-Orbitrap; ESI-[M−H]− |
| Phenolic acids and | Urine; SPE | Zorbax Eclipse C18 (4.6 × 150 mm, 1.8 μm); | QTOF; |
| Zorbax Eclipse C18 (4.6 × 150 mm, 1.8 μm); A: Water (10% FA), B: ACN. | QTOF; | ||
|
| |||
| Procyanidins [ | Plasma; PP; mixture | ACE Excel 2 C18-PFP (2.1 × 100 mm, 2 μm); A: Water (0.1% FA). B: ACN. | Q-Exactive; |
| Resveratrol [ | Plasma; PP; mixture | Nucleodur C18 Isis (2 × 150 mm,1.8 μm); A: Water, B: MeOH, both with 0.1% FA. | |
| Quercetin [ | Plasma; PP; Quercetin 4′- | Poroshell C18 (2.1 × 100 mm, 2.7 mm); A: Water, B: ACN, both with 0.1% FA. | QTOF; |
| Flavonoids [ | Urine; UD; Naringin-d4 | Kinetex C18 (3.0 × 150 mm, 2.6 μm); A: Water, B: MeOH, both with 0.1% FA. | QTOF; |
| Phenolic acids | Urine; LLE; Rutin and | Synergi Hydro RP18 C18 (2 × 150 mm, 4 μm); A: Water, B: ACN (0.1% FA). | LTQ-Orbitrap; ESI-[M−H]− |
| Isoflavones [ | Urine and plasma; SPE | Kinetex C18 (2.1 × 100 mm, 1.7 μm); A: Buffer (0.1% FA). B: ACN. | |
|
| |||
| Quercetin [ | Urine and plasma; PP | Acquity BEH C18 (2.1 × 50 mm, 1.7 μm); A: Water (0.1% FA). B: ACN, | QTOF; |
| Phenolic acids | Urine and plasma; µSPE; Taxifolin | Zorbax Eclipse Plus RRHD (2.1 × 50 mm, 1.8 µm); | |
| Phenolic acids | Urine and plasma; LLE, PP and UD | Ascentis Express C18 (3 × 150 mm, 2.7 μm); | |
| Phenolic acids [ | |||
| Flavan-3-ol [ | Urine and plasma; PP | Kinetex Phenyl-Hexyl (4.6 × 150 mm, 2.6 μm); 0.1% FA methanol in 0.1% aqueous FA | Q-Exactive; |
| Phenolic acids | Plasma; PP; Baicalin and | Acquity BEH C18 (2.1 × 150 mm, 1.7 μm); ACN (0.1% FA). | LTQ-Orbitrap; ESI-[M−H]− |
| Flavanone [ | Plasma; PP | Kinetex C18 (4.6 × 150 mm, 5 μm); | Q-Exactive; |
| Phenolic acids and flavonoids [ | Urine; UU | Zorbax Eclipse Plus C8 (2.1 mm × 100 mm, 1.8 μm); | QTOF; |
| Procyanidins, phenolic acids, and flavonols [ | Urine; UD | Luna C18 (2.0 × 50 mm, 5 μm); | LTQ-Orbitrap; ESI-[M−H]− |
| Flavan-3-ol [ | Urine; SPE: Hesperetin | Poroshell C18 (0.5 × 250 mm, 2.7 µm); | QTOF; |
AA: acetic acid; ACN: acetonitrile; FA: formic acid; UD: urine dilution; UU: unprocessed urine; SPE: solid-phase extraction; PP: protein precipitation; µSPE: micro-elution solid-phase extraction; * L-tryptophan-D3, L-leucine-D10, creatine-D3, and caffeine-D3; ** trans-resvératrol-13C6, trans-resveratrol-3-O-sulfate-D4, trans-resveratrol-3-O-β-d-glucuronide-D4, and trans-resveratrol-4′-O-β-d-glucuronide-D4.
Chromatographic and MS conditions for the quantification of PCM in plasma and urine samples.
| Phenolic Compounds | Sample; Sample Clean-Up; | Chromatographic Conditions | MS Conditions | LOQ |
|---|---|---|---|---|
|
| ||||
| Oleuropein [ | Plasma; SPE; | RP-C8 (150 × 2.1 mm, 3.5 μm); | QqQ; MRM; ESI-[M−H]− | 5–50 ng L−1 |
|
| ||||
| Flavonoids and phenolic acids [ | Plasma and urine; PP and UU; Ethyl gallate | Synergi RP-Max (4.6 × 250 mm, 4 μm); MeOH (0.5% AA or 1% FA). | QIT; FS, CRM, and SIM; ESI- [M−H]−/ [M+H]+ | |
| Flavonoids [ | Plasma and urine; | Symmetry C18 (2.1 × 50 mm, 3.5 μm); | QIT; FS; ESI- [M−H]−/ [M+H]+ | |
| Catechins [ | Urine; LLE | Supelcosil LC18 (3.0 × 100 mm, 5 μm); | QIT; FS; ESI- [M−H]− | |
| Phenolic acids [ | Plasma; PP; mixture | Acquity BEH C18 (2.1 × 150 mm, 1.7 μm); | QqQ; MRM; ESI- [M−H]− | 5 nM |
| Procyanidins [ | Plasma; SPE; Catechol | Acquity HSS T3 (2.1 × 100 mm, 1.8 μm); | QqQ; SRM; ESI- [M−H]− | 0.01–0.98 µM |
| Phenolic acids and alcohols and flavonoids [ | Plasma; µSPE; | Acquity BEH C18 (2.1 × 100 mm, 1.7 µm); | QqQ; SRM; ESI- [M−H]− | 0.02–8.2 µM |
| Phenolic alcohols [ | Urine; SPE; 4’- | Acquity BEH C18 (2.1 × 100 mm, 1.7 µm); | QqQ; MRM; ESI- [M−H]− | 1.87–20 ng L−1 |
| Resveratrol [ | Urine; UD; Wogonin | ODS-3 (5 × 150 mm, 2.1 μm); | QqQ; SRM; ESI- [M−H]− | 4–20 ng L−1 |
| (─)-Epicatechin [ | Plasma and urine; SPE; Umbelliferone sulfate and glucuronide | HSS C18 (1.8 × 100 mm, 2.1 μm); | QqQ; MRM; ESI- [M−H]− | 12–30 nM; |
| Phenyl-γ-valerolactone [ | Plasma and urine; PP and UD | Kinetex EVO C18 (2.1 × 100 mm, 2.6 μm); | QqQ; MRM; HESI- [M−H]− | 0.6–2.2 nM |
| Flavonoids and phenolic acids [ | ||||
| Daidzein and | Urine; LLE; Taxifolin | Phenomenex C18 (3 × 150 mm, 3 μm); | QTRAP; MRM; ESI- [M−H]− | 3 ng mL−1 |
| Luteolin [ | Plasma; PP | Capcell pak C18 MGII (4.6 × 150 mm, 3 μm); A: water (0.1% TFA), B: ACN. | QTRAP; MRM; ESI- [M+H]+ | |
|
| ||||
| Chlorogenic | Urine and plasma; PP; mixture solution * | Synergi Polar RP C18 (4.6 × 250 mm, 4 µm); A: Water, B: ACN, both with 0.1% AA. | QTRAP; MRM; ESI- [M−H]− | 5 nM |
| Flavonoids and | Plasma and urine; SPE and UU; Cyanidin-3- | Synergi Polar RP C18 (4.6 × 250 mm, 4 µm); MeOH (0.5% AA or 1% FA). | QIT; FS, SRM, SIM, and CRM; ESI-[M−H]−/ [M+H]+ | |
| Oleocanthal [ | Plasma; SPE | AcQuity BEH C18 (2.1 × 50 mm, 1.7 µm); | QqQ; MRM; ESI- [M−H]− | |
| Anthocyanins [ | Plasma and urine; SPE; Scopoletin | Kinetex PFP (4.6 × 100 mm, 2.6 μm); | QTRAP; MRM; ESI- [M+H]+ | |
|
| ||||
| Epicatechin, | Urine; SPE; Ethyl gallate | Luna C18 (2.0 × 50 mm, 5 μm); A: Water/ACN (94.9:5, | QqQ; MRM; ESI- [M−H]− | 0.03–44.4 μg L−1 |
| Flavanones [ | Urine; LLE | ACE 3 C18-AR (4.6 × 75 mm, 3 μm); | ||
|
| ||||
| Flavonoids and | Urine; LLE; Rutin and taxifolin | Atlantis T3 (2.1 × 100 mm, 3 µm); | QqQ; MRM; ESI- [M−H]− | |
| (─)-Epicatechin [ | Plasma and urine; | Luna C18 (2.0 × 50 mm, 5 µm); | QqQ; MRM; TIS- [M−H]− | |
| Flavonoids and phenolic acids [ | QqQ; MRM; ESI- [M−H]− | 28.4–75.8 ng L−1 | ||
| Flavonoids and | Plasma and urine; SPE and UD | Kinetex EVO C18 (2.1 × 100 mm, 2.6 μm); | QqQ; SRM; HESI- [M−H]− | |
| Flavan-3-ols [ | Urine; UD | QqQ; MRM; ESI- M−H]− | ||
| Phenolic acids [ | Plasma; SPE; Syringic acid | Pursuit 3 PFP (150 × 2.0 mm); | QqQ; MRM; ESI-[M−H]−/ M+H]+ | |
| Anthocyanins [ | Plasma; SPE; Malvidin-3- | Poroshell 120 C18 (2.1 mm × 150 mm, 2.7 μm); A: Water (1% FA), B: ACN. | ||
| Flavonoids, phenolic | Urine; SPE; Taxifolin | Luna Omega Polar C18 (100 × 2.1 mm, 1.6 μm); A: 10 mM ammonium formate (0.1% FA), B: ACN. | QTRAP; MRM; ESI- [M−H]− | 10 μg L−1 |
| Plasma; PP and SPE; Ferulic acid-1,2,3-13C3, L-phenylalanine-15N | Luna Omega Polar C18 (100 × 2.1 mm, 1.6 μm); A: Water, B: ACN, both with 0.5% FA. | QTRAP; MRM; ESI-[M+H]+ | 0.5–5 μmol L−1 | |
| Anthocyanins [ | Urine; SPE; Phloridzin, scopoletin, taxifolin, and 7,8-dihydroxycourmarin | Kinetex PFP (4.6 × 100 mm, 2.6 μm); | QTRAP; MRM; ESI-[M−H]− | |
AA: acetic acid; FA: formic acid; TFA: trifluoroacetic acid; SRM: selective reaction monitoring; SIM: selected ion monitoring, CRM: consecutive reaction monitoring; TIS: turbo ion spray; UD: urine dilution; UU: unprocessed urine; HESI: heated-electrospray ionization source. * d13C2-caffeic acid, d3-dihydroisoferulic acid, and d3-dihydroisoferulic-3′-O-glucuronide.